Microbiology News and Research

RSS

Accelr8 presents initial ICU pilot study results at ATS International Conference

Accelr8 Technology Corporation announced that clinical investigators led by Ivor S. Douglas, MD/FRCP (UK) from Denver Health presented initial ICU pilot study results at the 2011 ATS International Conference.

17 May 2011

New biomarker can predict breast cancer recurrence

Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker related to the body's immune system that can predict a breast cancer patients' risk of cancer recurrence.

17 May 2011

GenturaDx completes external HSV 1&2 alpha studies for IDbox System

Molecular diagnostics company GenturaDx announces the completion of external HSV 1&2 alpha studies for its IDbox instrument and cassette-based tests. Conducted at an external CLIA laboratory, the study analyzed more than 130 samples, including more than 70 clinical specimens.

16 May 2011

AgenoLAB acquires Roche´s RTCA Cardio Instrument

AgenoLAB, the Stuttgart-based service provider, is the first company in Germany to expand its service offering with the latest cell analysis technology from Roche. The company will use the RTCA Cardio Instrument to complement their analytical service portfolio for drug development.

13 May 2011

Zaire ebolavirus may replicate in pigs and transmit to other animals

Canadian investigators have shown that a species of ebolavirus from Zaire that is highly virulent in humans can replicate in pigs, cause disease, and be transmitted to animals previously unexposed to the virus.

13 May 2011

Shared wind instruments may cause sickness

Germs survive for several days in wind instruments including the clarinet, flute, and saxophone, according to a pilot study published in the International Journal of Environmental Health Research. The researchers, led by Stuart Levy, MD, of Tufts University School of Medicine, urge proper cleaning of these instruments.

13 May 2011

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Optimer Pharmaceuticals today announced the presentation of an additional analysis of data from the company's two Phase 3 clinical trials of DIFICID, an investigational antibiotic for the treatment of Clostridium difficile Infection, at the American Geriatric Society (AGS) Annual Meeting held in National Harbor, Maryland.

13 May 2011

Early antiretroviral treatment can halt HIV spread in couples

A research study led by the University of North Carolina at Chapel Hill has made a major discovery in the effort to halt the spread of HIV, the virus that causes AIDS.

13 May 2011

Mosquito's midgut bacteria can inhibit malaria parasite development

Researchers at the Johns Hopkins Bloomberg School of Public Health have identified a bacterium in field-caught mosquitoes that, when present, stops the development of Plasmodium falciparum, the parasite that causes malaria in humans.

13 May 2011

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, presented new clinical and pre-clinical data related to the safety and efficacy of its novel, lead defensin-mimetic antibiotic, PMX-30063.

12 May 2011

Salmonella enterica bacterium activates virulence genes through Fur protein

Salmonella enterica, one of the main causes of gastrointestinal infections, modulates its virulence gene expression, adapting it to each stage of the infection process, depending on the free iron concentration found in the intestinal epithelium of its host.

12 May 2011

Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference

Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 21st European Congress of Clinical Microbiology and Infectious Diseases conference in Milan, Italy highlighting additional analyses of the Phase 3 data of DIFICID for the treatment of Clostridium difficile infection.

11 May 2011

Dalbavancin surveillance antibiotic results for Gram-positive pathogens presented at ECCMID meeting

Durata Therapeutics today announced surveillance data demonstrating potency of the Company's lead antibiotic product, dalbavancin, a long-acting, intravenous lipoglycopeptide, against a broad spectrum of gram-positive bacteria prevalent in recent years.

10 May 2011

Tetraphase presents TP-434, TP-2758 antibiotics study data against pathogens at ECCMID

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.

10 May 2011

Pfizer presents SA3Ag staphylococcal vaccine Phase 1 trial data at ECCMID/ICC

Inhibitex, Inc., announced today that Pfizer Inc. presented safety and immunogenicity data from a Phase 1 double-blind randomized placebo controlled study in 408 healthy volunteers of a novel three antigen Staphylococcus aureus investigational vaccine at the 21st European Congress of Clinical Microbiology and Infectious Diseases and 27th International Congress of Chemotherapy in Milan, Italy.

10 May 2011

Parasites in human waste fertilizers alarm health experts

It has been suggested that human faeces used as fertiliser on farms are leading to the spread of ‘Third World’ parasites causing a serious stomach illness across Sydney.

8 May 2011

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the prestigious journal Current Opinion in Immunology has published an article in its current issue entitled, "Electroporation Delivery of DNA Vaccines: Prospects for Success."

7 May 2011

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic profile at IV doses up to 800 mg.

7 May 2011

New book explores the hidden world of viruses

"Carl Zimmer is one of the best science writers we have today. A Planet of Viruses is an important primer on the viruses living within and around all of us-sometimes funny, other times shocking, and always accessible. Whether discussing the common cold and flu, little-known viruses that attack bacteria or protect oceans, or the world's viral future as seen through our encounters with HIV or SARS, Zimmer's writing is lively, knowledgeable, and graced with poetic touches."-Rebecca Skloot, author of The Immortal Life of Henrietta Lacks.

7 May 2011

Latest research on HIV immunity can help develop vaccine

Latest insights into immunity to HIV could help to develop a vaccine to build antibodies' defences against the disease, a University of Melbourne, Australia study has found.

7 May 2011